|
KMID : 0857020020170010137
|
|
Kosin Medical Journal
2002 Volume.17 No. 1 p.137 ~ p.141
|
|
|
A Case of Rhabdomyolysis associated with Cerivastatin and Cyclosporine Combination Tharapy in a Kidney Transplant Recipient
|
|
Shin Seong-Hoon
Kim Min-Dae
Kang Seung-Su
Kim Chan-Ook
Lee Jee-Young
Eum Jae-Sup
Kwon Sung-Il
Kim Kil-Su
Jung Yeon-Soon
Rim Hark
|
|
|
Abstract
|
|
|
Cerivastatin, a kind of statins, is a recently used lipid-lowering drug. which inhibits of hydroxymethylglutarate coenzyme A (HMG-CoA) reductase. The serum concentrations of statins in healthy volunteers are increased by the simultaneous administration of cyclosporine, itraconazole, as well as erythromycin and verapamil and increased risk of myalgia and rhabdomyolysis has been reported after concomitant use of HMG-CoA reductase inhibitors with these drugs.
A 57-year-old female kidney transplant recipient admitted because of a dark urine, myalgia and weakness of extremities. Six weeks before admission, the patient has taken cerivastatin 0.3mg daily. Cyclosporine, prednisolone and mycophenolate mofetil were maintained for recent two years. Initial laboratory data showed serum creatinine 1.1mg/dl, AST 235 IU/L, LDH 2,465 IU/L, CPK 1600 IU/L, myoglobin >3,000 ng/ml and cyclosporine 288ng/ml (TDX). Medication of cerivastatin was discontinued, and the patient recovered rapidly with supportive therapy. After eighteen weeks of cerivastatin withdrawal. the drug was represcribed to control the increased lipid levels. The patient showed the same clinical manifestations suggesting rhabdomyolysis following eight weeks of cerivastatin administration.
We report a case of rhabdomyolysis associated with cerivastatin and cyclosporine combination therapy in a kidney transplant recipient.
|
|
|
KEYWORD
|
|
|
cerivastatin, cyclosporine, rhabdomyolysis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|